

زمانی میاسای ز آموختن
اگر جان، می خواهی افروختن



SOURCES OF PHARMACEUTIC AL INFORMATION?

Hossein Karballaei Mirzahosseini
Faculty of pharmacy



COMMENTARY · Volume 82, Issue 7, 6862, September 01, 2018

[Download Full Issue](#)

It's Time to Confront Student Mental Health Issues Associated with Smartphones and Social Media

[Jeff Cain, EdD, MS](#)  

[Affiliations & Notes](#)  [Article Info](#) 

 [Download PDF](#)  [Cite](#)  [Share](#)  [Set Alert](#)  [Get Rights](#)  [Reprints](#)

[Previous article](#) [Next article](#)

» Keywords

[smartphones](#) · [social media](#) · [mental health](#) · [anxiety](#) · [stress](#)

An increased focus on overall student health and wellness is one of the more recent evolutions in higher education. Pharmacy and other health professions colleges in particular have recognized that well-being is important for students preparing for high-stress health care careers. This awareness has prompted universities and colleges to proactively address risk factors for stress, depression and anxiety, and educate students about the importance of sleep, nutrition, exercise and hobbies.¹

Article metrics

31

Citations

193

Captures

2

55

The Prevalence of Addiction to Social Network Among Students in **Iran** and its Factors Related: A Study Conducted in 2020

[Hoorieh Rahiminia](#)^{1,2}, [Hamid Soori](#)^{1,3}, [Mahdi Jafari](#)^{4,5}, [Soheila Khodakarim](#)^{1,6,*}

► [Author information](#) ► [Article notes](#) ► [Copyright and License information](#)

PMCID: PMC8719277 PMID: [35136413](#)

Generally, 462 students **(44%)** had addiction to social networks, of which 449 (90.04%) had slight addiction and 13 (9.96%) had **severe addiction**

SOCIAL MEDIA ADDICTION



ما ده این رنبد گندم می کنیم

گندم جمع آنده کم می کنیم


اول ای جان دفع شرموش کن

واگهان ده جمع گندم کوش کن



SCIMAGO RESEARCH CENTERS RANKING

- The ranking spans **391 research centers** representing the **22** countries in the MENA region. It examines 16 indicators from 3 dimensions (Research, Innovation and Society).
- Journal Ranks
- Country Ranks
- Viz Tools



THE RANKING OF BEST JOURNALS FOR MEDICINE

Research.com

Rank	Journal Details		Best Scientists	Documents	Impact Score
1		The Lancet 0140-6736	3337	2497	172.30
2		New England Journal of Medicine 0028-4793	3269	3507	163.20
3		Nature Medicine 1078-8956	2131	1203	91.10
4		The Lancet Oncology 1470-2045	1541	1195	79.60
5		Journal of Clinical Oncology 0732-183X	3535	16668	79.30

ARTICLES · [Online first](#), November 25, 2024

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

[Prof Sunil V Badve, PhD](#) ^{a,b,c}  · [Anika Bilal, MD](#)^d · [Matthew M Y Lee, PhD](#)^e · [Prof Naveed Sattar, MD](#)^e · [Prof Hertzel C Gerstein, MD](#)^f · [Prof Christian T Ruff, MD MPH](#)^g · et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#)  [Linked Articles \(1\)](#) 



Get Access



Cite



Share



Set Alert



Get Rights



Reprints



How
Outline

Interpretation

We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

[Qingyang Shi, MM^{a,†}](#) · [Yang Wang, MB^{a,†}](#) · [Qiukui Hao, MD^{b,h}](#) · [Prof Per Olav Vandvik, MDⁱ](#) · [Prof Gordon Guyatt, MD^h](#) · [Jing Li, MD^a](#) et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#)  [Linked Articles \(1\)](#) 

Interpretation

In adults with overweight and obesity, phentermine–topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective.

ARTICLES · [Online first](#), 102920, November 14, 2024 · *Open Access*

Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review


[Mohsan Subhani](#) ^{a,b,m}  · [Ashwin Dhanda](#)^{c,m} · [James A. King](#)^{d,e,m} · [Fiona C. Warren](#)^f · [Siobhan Creanor](#)^f · [Melanie J. Davies](#)^{e,g} et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#) 

Interpretation

There is little high-quality evidence demonstrating the effect of GLP-1 RAs on alcohol use. Subgroup analysis from two RCTs and supporting data from four observational studies suggest that GLP-1 RAs may reduce alcohol consumption and improve outcomes in some individuals. Heterogeneous study findings warrant further research to establish the effectiveness and safety of GLP-1 RAs in this population.

BRAIN'S REWARD SYSTEM



> View all Commissions



Browse

Journals

[The Lancet](#)

[The Lancet Child & Adolescent Health](#)

[The Lancet Diabetes & Endocrinology](#)

[The Lancet Digital Health](#)

[The Lancet Gastroenterology & Hepatology](#)

[The Lancet Global Health](#)

[The Lancet Haematology](#)

[The Lancet Healthy Longevity](#)

[The Lancet HIV](#)

[The Lancet Infectious Diseases](#)

[The Lancet Microbe](#)

[The Lancet Neurology](#)

[The Lancet Oncology](#)

[The Lancet Planetary Health](#)

[The Lancet Psychiatry](#)

[The Lancet Public Health](#)

[The Lancet Regional Health – Americas](#)

[The Lancet Regional Health – Europe](#)

[The Lancet Regional Health – Southeast Asia](#)

[The Lancet Regional Health – Western Pacific](#)

[The Lancet Respiratory Medicine](#)

[The Lancet Rheumatology](#)

[eBioMedicine](#)

[eClinicalMedicine](#)

Rank	Journal Details		Best Scientists	Documents	Impact Score
6		JAMA - Journal of the American Medical Association 0098-7484	2165	2295	77.50
7		European Heart Journal 0195-668X	2328	10259	74.90
8		The Lancet Neurology 1474-4422	1041	717	68.80
9		Circulation 0009-7322	2960	9999	68.30
10		Journal of the American College of Cardiology 0735-1097	2299	9432	67.50

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

JAMA Network

JAMA®

Search All

Enter Search Term

Search

Sign In

JAMA®

Home


New Online

Issues

For Authors

Editor's Choice: Trends in Medical School Enrollment

Advertisement



Original Investigation

Association of Severe Maternal Morbidity With Subsequent Birth

Eleni Tsamantioti, MD, MMedSc; Anna Sandström, MD, PhD; Charlotte Lindblad Wollmann, MD, PhD; et al

Editorial

Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman's Choice

Anders Husby, MD, PhD; Heather A. Boyd, PhD

Get the latest from JAMA

Email address

Sign Up

Privacy Policy | Terms of Use

[f](#) [X](#) [@](#) [in](#) [v](#) [p](#) [RSS](#) [Podcast](#)

JAMA

JOURNALS

- JAMA[®]
- JAMA Network Open
- JAMA Cardiology
- JAMA Dermatology
- JAMA Health Forum
- JAMA Internal Medicine
- JAMA Neurology
- JAMA Oncology
- JAMA Ophthalmology
- JAMA Otolaryngology-Head & Neck Surgery

JAMA Pediatrics

JAMA Psychiatry

JAMA Surgery

Archives of Neurology & Psychiatry (1919-1959)

PODCASTS

Clinical Reviews

Editors' Summary

Medical News

Author Interviews

More



Original Investigation

November 18, 2024

Antidiabetic Medication and Asthma Attacks

Bohee Lee, PhD¹; Kenneth K. C. Man, PhD²; Ernie Wong, MD¹; [et al](#)

» [Author Affiliations](#)

JAMA Intern Med. Published online November 18, 2024. doi:10.1001/jamainternmed.2024.5982

Meaning The study results suggest that metformin was associated with a significant lowering of asthma attacks and the addition of glucagon-like peptide-1 receptor agonists was associated with a synergistic additive effect.

November 20, 2024

Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk

Xavier Sendaydiego, MD¹; Laura S. Gold, PhD^{2,3}; Maureen Dubreuil, MD, MSc^{4,5}; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA Netw Open. 2024;7(11):e2446336. doi:10.1001/jamanetworkopen.2024.46336

Findings In this cohort study consisting of 25 305 individuals who initiated treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs, a statistically significantly higher risk of incident cancer was seen with rituximab, abatacept, and JAKis compared with TNFis. Individuals initiating rituximab likely had a higher risk of incident cancer due to channeling bias, rather than the drug itself increasing cancer risk.

Original Investigation | Pharmacy and Clinical Pharmacology

January 4, 2024

Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes

Rachel Dankner, MD, MPH^{1,2}; Havi Murad, PhD³; Nirit Agay, PhD^{1,3}; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA Netw Open. 2024;7(1):e2350408. doi:10.1001/jamanetworkopen.2023.50408

Findings In this cohort study of 543 595 patients, compared with treatment with basal insulin, treatment of comparable patients with type 2 diabetes with GLP-1RA was not associated with excess risk of pancreatic cancer.

Original Investigation

October 21, 2024

Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor-Inhibitor Treatment for Autoimmune Diseases A Systematic Review and Meta-Analysis

Wenhui Xie, PhD^{1,2}; Yunchuang Sun, MD³; Wei Zhang, MD⁴; [et al](#)

Findings This systematic review and meta-analysis of 18 studies including more than 1 million patients with autoimmune diseases revealed that exposure to TNF inhibitors was associated with 36% increased risk of inflammatory CNS diseases, especially demyelinating diseases. The risk of inflammatory CNS events following anti-TNF therapy did not differ by types of autoimmune diseases or prescribed TNF inhibitors.

Original Investigation

September 30, 2024

Antiseizure Medications and Cardiovascular Events in Older People With Epilepsy

Jimmy Li, MD^{1,2}; Nathan A. Shlobin, MD³; Roland D. Thijs, MD, PhD^{4,5,6}; [et al](#)

» [Author Affiliations](#)

JAMA Neurol. 2024;81(11):1178-1186. doi:10.1001/jamaneurol.2024.3210

Findings This cohort study included 27 230 individuals and, using the Canadian Longitudinal Study on Aging, found that adults with a lifetime history of epilepsy were approximately 2 times more likely to report new CVEs, including strokes, transient ischemic attacks, and myocardial infarctions, over 6 years. Almost one-third of this association may result from EIASM use.

Original Investigation | Nephrology

August 20, 2024

Sacubitril-Valsartan in Patients Requiring Hemodialysis

Dustin Le, MD, MHS¹; Morgan E. Grams, MD, PhD²; Josef Coresh, MD, PhD³; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA Netw Open. 2024;7(8):e2429237. doi:10.1001/jamanetworkopen.2024.29237

Findings In this comparative effectiveness research study of 1434 patient pairs, initiation of sacubitril-valsartan therapy was associated with a statistically significant 18% reduction in all-cause mortality and 14% reduction in all-cause hospitalization.

March 19, 2024

Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis

A Randomized Clinical Trial

Tracey G. Simon, MD, MPH^{1,2,3}; Robert M. Wilechansky, MD^{1,2,4}; Stefania Stoyanova, BA⁴; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA. 2024;331(11):920-929. doi:10.1001/jama.2024.1215

Conclusions and Relevance In this preliminary randomized clinical trial of patients with MASLD, 6 months of daily low-dose aspirin significantly reduced hepatic fat quantity compared with placebo. Further study in a larger sample size is necessary to confirm these findings.

April 15, 2024

Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban

Wayne A. Ray, PhD¹; Cecilia P. Chung, MD, MPH^{2,3}; C. Michael Stein, MB, ChB^{4,5}; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA. 2024;331(18):1565-1575. doi:10.1001/jama.2024.3867

Findings In this cohort study of 204155 patients aged 65 years or older, those treated with diltiazem had a significantly greater risk of serious bleeding compared with those treated with metoprolol.

Conclusions and Relevance In Medicare patients with atrial fibrillation receiving apixaban or rivaroxaban, diltiazem was associated with greater risk of serious bleeding than metoprolol, particularly for diltiazem doses exceeding 120 mg/d.



The NEW ENGLAND
JOURNAL of MEDICINE

SPECIALTIES ▾

TOPICS ▾

MULTIMEDIA ▾

CURRENT ISSUE ▾

LEARNING/CME ▾

AUTHOR CENTER

PUBLICATIONS ▾

ORIGINAL ARTICLE



Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections

Author: The BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network* [Author Info & Affiliations](#)



Published November 20, 2024 | DOI: 10.1056/NEJMoa2404991 | Copyright © 2024



ORIGINAL ARTICLE



Routine Spironolactone in Acute Myocardial Infarction

Authors: Sanjit S. Jolly, M.D. , Marc-André d'Entremont, M.D., M.P.H., Bertram Pitt, M.D., Shun Fu Lee, Ph.D., Rajibul Mian, Ph.D., Jessica Tyrwhitt, B.Sc., Sasko Kedev, M.D., Ph.D., , for the CLEAR investigators* [Author Info & Affiliations](#)

Published November 17, 2024 | DOI: 10.1056/NEJMoa2405923 | Copyright © 2024

RESULTS

We enrolled 7062 patients at 104 centers in 14 countries; 3537 patients were assigned to receive spironolactone and 3525 to receive placebo. At the time of our analyses, the vital status was unknown for 45 patients (0.6%). For the first primary outcome, there were 183 events (1.7 per 100 patient-years) in the spironolactone group as compared with 220 events (2.1 per 100 patient-years) in the placebo group over a median follow-up period of 3 years (hazard ratio adjusted for competing risk of death from noncardiovascular causes, 0.91; 95% confidence interval [CI], 0.69 to 1.21; $P=0.51$). With respect to the second primary outcome, an event occurred in 280 of 3537 patients (7.9%) in the spironolactone group and 294 of 3525 patients (8.3%) in the placebo group (hazard ratio adjusted for competing risk, 0.96; 95% CI, 0.81 to 1.13; $P=0.60$). Serious adverse events were reported in 255 patients (7.2%) in the spironolactone group and 241 (6.8%) in the placebo group.



The NEW ENGLAND
JOURNAL of MEDICINE

SPECIALTIES ▾

TOPICS ▾

MULTIMEDIA ▾

CURRENT ISSUE ▾

LEARNING/CME ▾

AUTHOR CENTER


PUBLICATIONS ▾



VIDEOS IN CLINICAL MEDICINE



Epidural Glucocorticoid Injection for Lumbosacral Radicular Pain

Authors: David Hao, M.D. , R. Jason Yong, M.D., Samer Narouze, M.D., Alexandra E. Fogarty, M.D., Olivia M. Sutton, M.D., and Milan P. Stojanovic, M.D. [Author Info & Affiliations](#)

Published November 6, 2024 | N Engl J Med 2024;391: e38 | DOI: 10.1056/NEJMvcm2313448 | **VOL. 391 NO. 18**



Copyright © 2024



ORIGINAL ARTICLE



A Randomized Trial of Intravenous Amino Acids for Kidney Protection

Authors: Giovanni Landoni, M.D., Fabrizio Monaco, M.D., Lian Kah Ti, M.B., B.S., M.Med., Martina Baiardo Redaelli, M.D., Nikola Bradic, M.D., Marco Comis, M.D., Yuki Kotani, M.D. , , for the PROTECTION Study Group* [Author Info & Affiliations](#)

Published June 12, 2024 | N Engl J Med 2024;391:687-698 | DOI: 10.1056/NEJMoa2403769 | [VOL. 391 NO. 8](#)

Copyright © 2024

CONCLUSIONS

Among adult patients undergoing cardiac surgery, infusion of amino acids reduced the occurrence of AKI. (Funded by the Italian Ministry of Health; PROTECTION ClinicalTrials.gov number, [NCT03709264](#).)

[nature](#) > [news](#) > article

NEWS | 26 September 2024

Stem cells reverse woman's diabetes — a world first

Patient is the first person with type 1 diabetes to receive this kind of transplant.

[nature](#) > [nature medicine](#) > [news feature](#) > [article](#)

News Feature | Published: 04 September 2024

Hibernation science harnessed to treat obesity and modify metabolism

[Carrie Arnold](#)

[Nature Medicine](#) **30**, 2700–2703 (2024) | [Cite this article](#)

2447 Accesses | **16** Altmetric | [Metrics](#)

By understanding the biology of hibernating animals, scientists are developing new treatments to trigger weight loss and alter metabolic pathways.

HIBERNATION



[nature](#) > [nature medicine](#) > [brief communications](#) > article

Brief Communication | [Open access](#) | Published: 25 July 2024

The recombinant shingles vaccine is associated with lower risk of dementia

[Maxime Taquet](#) , [Quentin Dercon](#), [John A. Todd](#) & [Paul J. Harrison](#) 

[Nature Medicine](#) **30**, 2777–2781 (2024) | [Cite this article](#)

42k Accesses | **4** Citations | **3025** Altmetric | [Metrics](#)

[nature](#) > [nature medicine](#) > [editorials](#) > article

Editorial | Published: 19 April 2024

Microplastics are everywhere – we need to understand how they affect human health

[Nature Medicine](#) **30**, 913 (2024) | [Cite this article](#)

39k Accesses | **6** Citations | **899** Altmetric | [Metrics](#)

As evidence emerges describing the accumulation of small plastic particles in various organs and tissues of the body, a much deeper understanding of the effects of these particles on human health is urgently needed.

MICROPLASTICS ARE EVERYWHERE


nearly 60% of about 250 people who were undergoing **heart surgery** had micro- or nanoplastics in a **main artery**.



YOUR BRAIN IS FULL OF MICROPLASTICS: ARE THEY HARMING YOU?

Plastics have infiltrated every recess of the planet, including your lungs, kidneys and other sensitive organs. Scientists are scrambling to understand their effects on health

Microplastics Linked to Heart Attack, Stroke and Death



EFFECTS OF MICROPLASTICS ON MENTAL HEALTH

Studies have shown that exposure to microplastics can lead to changes in behavior, neurotoxicity, and cognitive impairments in animal models.



[nature](#) > [nature reviews drug discovery](#) > [news in brief](#) > article











NEWS IN BRIEF | 26 September 2024 | Update [27 September 2024](#)

FDA approves first schizophrenia drug with new mechanism of action since 1950s

By [Katie Kingwell](#)



Sign up to N

Pharmaceutical Journals											
	Title	Type	↓ SJR	H index	Total Docs. (2023)	Total Docs. (3years)	Total Refs. (2023)	Total Cites (3years)	Citable Docs. (3years)	Cites / Doc. (2years)	F
1	American Journal of Pharmaceutical Education 	journal	1.110 	78	279	494	3042	1263	404	1.74	
2	Journal of Pharmaceutical Analysis 	journal	1.068 	51	121	247	9301	1852	245	6.09	
3	Research in Social and Administrative Pharmacy	journal	0.833 	69	167	747	8486	2511	621	3.79	
4	Journal of managed care & specialty pharmacy	journal	0.766 	75	149	549	4254	1052	493	2.09	
5	Journal of Pharmaceutical Policy and Practice 	journal	0.740 	32	165	291	6518	936	256	2.71	
6	Journal of the American Pharmacists Association : JAPhA	journal	0.593 	73	266	803	7419	1409	658	1.83	
7	International Journal of Clinical Pharmacy	journal	0.577 	71	163	513	6171	1192	464	2.30	

Rank	Journal	Impact Factor
1	Nature Reviews Drug Discovery	ca. 122.7
2	Pharmacological Reviews	ca. 19.3
3	Drug Resistance Updates	ca. 15.8
4	Advanced Drug Delivery Reviews	ca. 15.2
5	Acta Pharmaceutica Sinica B	ca. 14.7
6	Trends in Pharmacological Sciences	ca. 13.9
7	Drugs	ca. 13
8	Pharmacology & Therapeutics	ca. 12
9	Annual Review of Pharmacology and Toxicology	ca. 11.2
10	Medicinal Research Reviews	ca. 10.9
11	Asian Journal of Pharmaceutical Sciences	ca. 10.7
12	Journal of Controlled Release	ca. 10.5
13	Pharmacological Research	ca. 9.1
14	PLoS ONE	ca. 5.1

	Publication	<u>h5-index</u>	<u>h5-median</u>
1.	Nature Reviews Drug Discovery	<u>136</u>	324
2.	Frontiers in Pharmacology	<u>133</u>	184
3.	Journal of controlled release	<u>125</u>	172
4.	Advanced Drug Delivery Reviews	<u>113</u>	174
5.	Pharmacological Research	<u>113</u>	149
6.	Journal of Medicinal Chemistry	<u>112</u>	165
7.	Pharmaceutics	<u>111</u>	153
8.	Pharmacology & Therapeutics	<u>99</u>	139
9.	International Journal of Nanomedicine	<u>99</u>	138
10.	International Journal of Pharmaceutics	<u>99</u>	128
11.	Acta Pharmaceutica Sinica B	<u>96</u>	152
12.	Drugs	<u>94</u>	141
13.	Membranes	<u>93</u>	115

[nature](#) > [nature reviews drug discovery](#) > [review articles](#) > [article](#)

Review Article | Published: 11 September 2024

Targeting cytokine networks in neuroinflammatory diseases

[Burkhard Becher](#) , [Tobias Derfuss](#)  & [Roland Liblau](#) 

[Nature Reviews Drug Discovery](#) **23**, 862–879 (2024) | [Cite this article](#)

3848 Accesses | **26** Altmetric | [Metrics](#)

Abstract

Sections

[Figures](#)

[References](#)

[Abstract](#)

[References](#)

[Acknowledgements](#)

A large banner image featuring a close-up of a white, oval-shaped pill with a textured surface. The text "Frontiers in Pharmacology" is overlaid in white. Below the title, there are three dark grey boxes containing metrics: "4.4 Impact Factor", "7.8 CiteScore", and "356,000 Citations". To the right of these boxes is a blue button with the text "Submit →".

Frontiers in Pharmacology

4.4

Impact Factor

7.8

CiteScore

356,000

Citations

[Submit](#) →

Community driven journals

Join our editorial board and collaborate with a team of independent researchers from around the world, carefully selected for their field expertise.

[Editorial board](#) >



Advanced Drug Delivery Reviews

Supports open access

28.1

CiteScore

15.2

Impact Factor

[Articles & Issues](#) ▼

[About](#) ▼

[Publish](#) ▼

[Order journal](#) ↗

[Search in this journal](#)

[Submit your article](#) ↗

[Guide for authors](#)

About the journal

The aim of the Journal is to provide a forum for the critical analysis of advanced **drug** and **gene delivery** systems and their applications in **human** and **veterinary medicine**. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to ...

[View full aims & scope](#)



Access through your organization

Purchase PDF

Patient Access



ELSEVIER

Advanced Drug Delivery Reviews

Available online 17 November 2024, 115473

In Press, Journal Pre-proof [What's this?](#)



DRUG DELIVERY SYSTEMS FOR TREATING NEURODEVELOPMENTAL DISORDERS

Boaz Barak^{a, b}, Paolo Decuzzi^{c, d}

[Show more](#)

Part of special issue

[An integrated perspective for the
diagnosis and therapy in
neurodevelopmental disorders](#)

Edited by Paolo Decuzzi, Boaz Barak,

Commissioned by Maria J. Vicent



[View special issue](#)

[Recommended articles](#)

CRISPR HAS FINALLY WON A NOBEL PRIZE

WHAT IS CRISPR: THE ULTIMATE GUIDE TO CRISPR MECHANISMS,
APPLICATIONS, METHODS & MORE

Nobel Prize Awarded to Jennifer Doudna And Emmanuelle Charpentier For CRISPR Discovery

9 MIN READ • MEENAKSHI PRABHUNE, PH.D.

The wait has come to an end. CRISPR has finally won a Nobel Prize. Jennifer Doudna and Emmanuelle Charpentier have been awarded the ultimate science prize for their breakthrough research on CRISPR technology. Learn about their scientific journey as well as the vital contributions of other scientists that paved the way for the emergence of CRISPR as the most




New Feature!

Create gamified, interactive views of the current web page for better understanding


CRISPR (CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS)





JENNIFER DOUDNA

CRISPR in Clinical Trials — 2024



CASGEVY

is a **gene therapy** approved for the treatment of **sickle cell disease** and **transfusion-dependent beta-thalassemia** in patients **12** years of age and older.

It utilizes **CRISPR/Cas9 gene-editing technology** to modify a patient's own **blood stem cells, enabling them to produce a type of hemoglobin** that can help correct the underlying genetic defects in these blood disorders.

CASGEVY

exagamglogene autotemcel



CLINICAL TRIAL FOR CASGEVY

a gene therapy for **sickle cell disease**, **97%** of patients were **free from severe pain crises** for at least **12 months** after treatment. In the trial for **transfusion-dependent β -thalassemia**, **93%** of patients did **not need red blood cell transfusions for at least 12 months**. These results highlight the potential of Casgevy to significantly reduce the burden of these diseases.





به آب زمزم و کوثر سفید نتوان کرد
گلیم بخت کسی را که بافتند سیاه


حافظ

THE FIRST EVER **CANCER VACCINE** SHOWS POSITIVE RESULTS

The **mRNA-based vaccine** for cancer showed promising results in human trials. This innovative vaccine directs the immune response to identify and destroy cancer cells, thereby **reducing the chance of recurrence in lung, breast, and pancreatic cancers.**



ARTIFICIAL ORGANS GROWN IN LABS



ARTIFICIAL ORGANS GROWN IN LABS

Organ researchers are now able to bioprint fully functioning artificial human organs such as **kidneys and livers using stem cell technology**. This breakthrough can change the waiting time people must endure for actual **organ transplants and can save millions of lives**


MELANOMAS MIGHT SOON BE CURED BY USING TUMOR CELLS

AMTAGVI

A single dose of AMTAGVI contains 7.5×10^9 to 72×10^9 viable cells. AMTAGVI treatment regimen consists of lymphodepletion followed by AMTAGVI infusion followed by IL-2 (aldesleukin) administration.

AMTAGVI returns billions of the patient's T cells back to the body to fight their cancer. The specific mechanism of action is unknown.

AMTAGVI



میاسای ز آموختن یک زمان

زدانش میکن دل اندر گمان

فردوسی

